1 / 8

Daily Equity Report 24 JULY 2019

capitalstars is a financial research company in India who provide commodity market tips, Commodity Premium reports ,This service is basically for long term Traders.<br>http://www.capitalstars.com/bullion-premium-mcx-tips/<br>

PeehuSharma
Télécharger la présentation

Daily Equity Report 24 JULY 2019

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. CAPITALSTARS FINANCIAL RESEARCH PVT. LTD. CapitalStars Investment Adviser: SEBI Registration Number: INA000001647 DAILY EQUITY REPORT 24 THJULY 2019 Investment & trading in securities market is always subjected to market risks, past performance is not a guarantee of future performance.

  2. CAPITALSTARS FINANCIAL RESEARCH PVT. LTD. Daily Equity Report INDIAN FACE INDIAN MARKET CLOSE PREVIOUS ! 38031.13 INDIAN EQUITY BENCHMARK - Benchmark indices ended lower for the fourth consecutive day on July 23 as it remained volatile throughout the day with Nifty failed to NIFTY 11346.20 hold above 11,350 level. At close, the Sensex was down 48.39 CLOSE PREVIOUS points at 37,982.74, while Nifty was down 15.20 points at NIKKEI 21416.79 11,331. About 1170 shares have advanced, 1259 shares declined, and 168 shares are unchanged. SBI, Indiabulls 28371.26 Housing, HDFC, Adani Ports and Bajaj Auto were among 2101.45 major losers on the Nifty, while gainers were Power Grid SECTORIAL INDICES Corp, Kotak Mahindra Bank, ITC, Hero Motocorp and Asian CLOSE Paints. Among sectors, PSU banks dragged 3 percent CNX 100 11436.55 followed by auto, metal, pharma, while buying seen in the S&P CNX 500 FMCG, energy, infra and IT. GLOBAL FACE CNX 200 ! BANK NIFTY 29128.10 Asian Market - Asian markets finished higher today with shares in Japan leading the region. The Nikkei 225 is up 0.95% while China's Shanghai Composite is up 0.45% and TOP GAINERS Hong Kong's Hang Seng is up 0.34%. CLOSE CHANGE (%) ! U.S. Market – North and South American markets finished mixed as of the most recent closing prices. The Bovespa gained 0.48% and the S&P 500 rose 0.28%. The IPC lost KOTAKBANK HEROMOTOCO 0.95%. ! TOP LOSERS European markets – European markets are broadly higher today with shares in Germany leading the region. The DAX is CLOSE up 1.51% while France's CAC 40 is up 0.69% and London's FTSE 100 is up 0.52%. SBIN -2.20 -2.14 -1.69 Investment & trading in securities market is always subjected to market risks, past performance is not a guarantee of future performance.

  3. CAPITALSTARS FINANCIAL RESEARCH PVT. LTD. Daily Equity Report NIFTY SPOT MARKET MOVERS UPSIDE STRATEGY SELL ON RISE SCRIPT CLOSE (%) 2.89 210.00 POWERGRID PIVOT POINTS P 11344 S3 11153 S2 11248 S1 R1 11385 R2 11439 RESISTANCE R1-11480 R2-11600 R3 11534 270.95 2.48 11289 132.90 1.57 SUPPORT S1-11200 S2-11100 359.00 1.56 MARKET MOVERS DOWNSIDE CLOSE (%) SBIN HDFCBANK GRASIM NET BUY (CR.) NET INSTITUTION SELL (CR) FII 5332.62 TREND STRATEGY SELL ON RISE 2835.60 PIVOT POINTS P 29251 SUPPORT S2 28939 S1 29063 R2 R3 29874 NSE TOTALS 28627 29375 29563 RESISTANCE R1-29380 R2-29550 DECLINE S INDICES BANK NIFTY NIFTY 2 Investment & trading in securities market is always subjected to market risks, past performance is not a guarantee of future performance.

  4. CAPITALSTARS FINANCIAL RESEARCH PVT. LTD. Daily Equity Report MARKET TALKS ! Dr Reddys launches Tablets in the US Tier-I capital on July 30 Shares of PNB Housing Finance are trading flat with a positive bias as the company announced that it would consider raising tier-I capital. The company in its filing on the NSE said, "...We wish to further inform you that in the same Meeting, the Board shall also consider the approval of raising of tier-1 capital by issue of Equity Shares and/or any other financial instruments through preferential issue, qualified institutions placement, rights issue or through any other permissible mode and/or combination thereof as may be considered appropriate, subject to such approvals as may be required including the approval of the shareholders at a general meeting or through postal ballot and further subject to such other statutory/regulatory approvals, as applicable." Dr. Reddy's Laboratories Ltd., along with its subsidiaries together today post market hours announced the launch of Ramelteon Tablets, 8 mg, a therapeutically equivalent generic version of Rozerem (ramelteon, 8 mg) Tablets, approved by the US Food and Drug Administration (USFDA). The Rozerem brand had US sales of ~$91.3mn MAT for the most recent twelve months ending in May 2019 according to IQVIA Health. Dr. Reddy's Ramelteon Tablets, are available as 8 mg tablets in bottle count sizes of 30, 100, and 1000. Rozerem is a trademark of Takeda Pharmaceutical Company Limited. ! HDFC Life Insurance Q1FY20 PAT up 11.7% yoy at Rs424.6cr HDFC Life Insurance Company Limited (formerly HDFC Standard Life Insurance Company Limited) posted a net profit of Rs424.6cr, up 11.7% yoy in Q1FY20. The individual annualized premium equivalent (APE) was up by 64% yoy to Rs1,378cr in Q1. The new business premium rose by 47% yoy to Rs3,926cr in the June quarter. The company said in a press note, We are one of the leading fund managers in India with an AUM of around Rs1.3 lakh cr; debt/equity mix as on June 30, 2019, is 62:38. Almost 96% of debt investments are in GSecs and AAA bonds as on June 30, 2019. ! Alembic Pharma up 2% on receiving USFDA tentative approval for Dapagliflozin tablets Alembic Pharmaceuticals Limited today announced that the Company has received tentative approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Dapagliflozin Tablets, 5 mg and 10 mg.Shares of the company are trading 2% higher post the announcement. The approved ANDA is therapeutically equivalent to the reference listed drug (RLD) Farxiga Tablets, 5 mg and 10 mg, of AstraZeneca AB (AstraZeneca). Investment & trading in securities market is always subjected to market risks, past performance is not a guarantee of future performance.

  5. CAPITALSTARS FINANCIAL RESEARCH PVT. LTD. Daily Equity Report NAME OF THE STOCK : CANFINHOME DATE : 24/07/2019 SEGMENT : CASH CHART TYPE : Candlestick EXCHANGE : NSE TECHNICAL INDICATORS USED : VOLUME.MACD,RSI. CHART INVESTMENT ADVICE: CALL CS CALL:- BUY CANFINHOME IN CASH ABOVE 407 TGT 416 SL 398 RATIONALE FOR ARRIVING INVESTMENT ADVICE : TECHNICAL VIEW : THE STOCK TECHINCALLY IS UP ,TAKING SUPPORT OF VOLUME.RESISTANCE IS BROKEN TODAY WITH HEAVY VOLUME.AS WELL AS A POSSIBILITY OF UPWARD MOVEMENT IS THERE. OTHER REASON IF ANY :- SHOWING STRENGTHS IN INTRADAY CHARTS AS WELL Investment & trading in securities market is always subjected to market risks, past performance is not a guarantee of future performance.

  6. CAPITALSTARS FINANCIAL RESEARCH PVT. LTD. DISCLAIMER The information and views in this report & all the service we provide are believed to be reliable, but we do not accept any responsibility for errors of fact or opinion. Investors have the right to choose the product/s that suits them the most. Sincere efforts have been made to present the right investment perspective. The information contained herein is based on analysis and up on sources that we consider reliable. This material is for personal information and based upon it & takes no responsibility. The information given herein should be treated as only factor, while making investment decision. The report does not provide individually tailor-made investment advice. My research recommends that investors independently evaluate particular investments and strategies, and encourages investors to seek the advice of a financial adviser. CapitalStars shall not be responsible for any transaction conducted based on the information given in this report, which is in violation of rules and regulations of regulators. The price projections shown are not necessarily indicative of future price performance. The information herein, together with all estimates and forecasts, can change without notice. It is understood that anyone who is browsing through the site has done so at his free will and does not read any views expressed as a recommendation for which either the site or its owners or anyone can be held responsible for. Investment & Trading in Securities Markets are always subjected to market risk. CapitalStars Financial Research Private Ltd., Reserves all Rights. INVESTMENT AND TRADING IN SECURITIES MARKET IS ALWAYS SUBJECTED TO MARKET RISK. Investment & trading in securities market is always subjected to market risks, past performance is not a guarantee of future performance.

  7. CAPITALSTARS FINANCIAL RESEARCH PVT. LTD. CapitalStars Financial Research Private Limited is an advisory company incepted with a vision of providing fair and accurate trading and investment calls in share and commodity market. we specialize in thorough fundamental and technical research analysis in equity and commodity market to provide best equity and commodity tips to traders and investors. we provide intraday as well as delivery stock tips in NSE and BSE and commodity tips in MCX and NCDEX. Get our more services:- Intraday stock tips Financial advisory company Sharemarket company Stock Tips Investment & Trading in securities market is always subjected to market risks, past performance is not a guarantee of future performance. CapitalStars Investment Adviser: SEBI Registration Number: INA000001647

  8. CAPITALSTARS FINANCIAL RESEARCH PVT. LTD. BRANCH OFFICE Capitalstars Financial Research Private Limited PLOT NO.32, MECHANIC NAGAR EXTENSION,IDA SCHEME NO.54,VIJAYNAGAR INDORE REGISTERED OFFICE PLOT NO.12, SCHEME NO.78 PART-2, VIJAY NAGAR, INDORE Email:-backoffice@capiltalstars.in Contact us :- 9977499927, 9039012727 Report Is Checked by Investment Advisor: Investment & trading in securities market is always subjected to market risks, past performance is not a guarantee of future performance.

More Related